Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Ранг среди акций #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Цена акции
$207.15
Рыночная капитализация
$366.28B
Изменение (1 день)
0.99%
Изменение (1 год)
2.91%
Страна
US
Торговля AbbVie Inc. (ABBV)

Категория

История дивидендов AbbVie Inc. (ABBV)
AbbVie Inc. (тикер: ABBV) выплатила в общей сложности 53 дивидендов.
Общая сумма всех дивидендов (с учетом дроблений акций): $53.96
Дивидендная доходность (TTM): 0.0303
Дивидендные выплаты по AbbVie Inc. (ABBV) с 2013 по 2026
Годовые дивидендные выплаты
Год Дивиденды (с учетом дробления акций) Изменить
2026 (TTM) $1.73 -73.63%
2025 $6.56 5.81%
2024 $6.20 4.73%
2023 $5.92 4.96%
2022 $5.64 8.46%
2021 $5.20 10.17%
2020 $4.72 10.28%
2019 $4.28 19.22%
2018 $3.59 40.23%
2017 $2.56 12.28%
2016 $2.28 12.87%
2015 $2.02 21.69%
2014 $1.66 3.75%
2013 $1.60 0.00%
Список всех дивидендных выплат
Год Дивиденд Изменить
2026 (TTM) $1.73 -73.63%
2025 $6.56 5.81%
2024 $6.20 4.73%
2023 $5.92 4.96%
2022 $5.64 8.46%
2021 $5.20 10.17%
2020 $4.72 10.28%
2019 $4.28 19.22%
2018 $3.59 40.23%
2017 $2.56 12.28%
2016 $2.28 12.87%
2015 $2.02 21.69%
2014 $1.66 3.75%
2013 $1.60 0.00%
Дивиденды аналогичных компаний или конкурентов
Компания Количество дивидендных выплат Страна
215.00%
US
67.00%
GB
225.00%
US
32.00%
CH
223.00%
US